Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE003 (CAN) (Dr. Okafor)
· consented 2022-11-02
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
severe
serious
assessed
2026-08-18
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 133); relationship: N; serious criteria: life-threatening
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-09 (study day 240); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-07-04 (study day 601); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-11-08 (study day 728); relationship: N
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-11-14 (study day 734); relationship: N
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-12-27 (study day 777); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.